quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:22:16·51d
ANALYSTRating
AgomAb Therapeutics NV logo

Leerink Partners initiated coverage on AgomAb Therapeutics NV with a new price target

AGMB· AgomAb Therapeutics NV
Health Care
Original source

Companies

  • AGMB
    AgomAb Therapeutics NV
    Health Care

Recent analyst ratings

  • Mar 3UpdateAnalyst$32.00
  • Mar 3UpdateMorgan Stanley$28.00
  • Mar 3UpdateLeerink Partners$36.00

Related

  • PR5h
    Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
  • SEC6h
    SEC Form 20-F filed by AgomAb Therapeutics NV
  • SEC7d
    SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV
  • PR28d
    Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
  • INSIDER36d
    SEC Form 3 filed by new insider Bond Colin Michael
  • INSIDER36d
    SEC Form 3 filed by new insider Van Der Horst Paul Henryk
  • INSIDER36d
    SEC Form 3 filed by new insider Knotnerus Tim Jasper
  • INSIDER36d
    SEC Form 3 filed by new insider Borderias Andrea Saez
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022